Retatrutide (R3TA) and semaglutide are two of the most-studied incretin-pathway peptides in current research, but they are mechanistically distinct. This guide compares them in a research context.
The core difference
Semaglutide is a single-receptor agonist that acts on the GLP-1 receptor. Retatrutide is a triple agonist, engaging the GLP-1, GIP and glucagon receptors together. That difference in receptor targeting is the main reason researchers study the two side by side.
Why researchers compare them
Because semaglutide is well-characterised in the literature, it is frequently used as a reference point when newer multi-receptor peptides such as retatrutide are evaluated in preclinical models. Comparisons typically focus on receptor selectivity, pharmacokinetics, and stability rather than any human outcome.
Handling and verification
Both are supplied as lyophilised powders requiring reconstitution with bacteriostatic water for research use. Whichever you study, insist on a Certificate of Analysis confirming identity and purity for the specific batch.
For research use only. Not for human or animal consumption. Sold to qualified researchers, 18+.
Frequently asked questions
Is retatrutide the same class as semaglutide?
They act on overlapping pathways but are not the same class. Semaglutide is a single GLP-1 receptor agonist; retatrutide is a triple GLP-1/GIP/glucagon receptor agonist. This is a research comparison only.
Why do researchers study them together?
Semaglutide is well-characterised in the literature, so it is often used as a reference when newer multi-receptor peptides such as retatrutide are evaluated in preclinical research.
Are both third-party tested at Vero Labs?
Yes. Every batch of both is supplied with a Certificate of Analysis verifying identity and purity. All products are for research use only.
R3TA (Retatrutide) — lab-tested, COA available
Every batch is third-party tested for identity and purity. Same-day NZ dispatch.